Markets:

Overview

News

Currencies

International

Treasuries

Novartis AG Common Stock (NY:NVS)

150.68 +1.53 (+1.03%)

Streaming Delayed Price Updated: 10:36 AM EDT, May 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

56 57 Next >

3 International ETFs for Investors Looking Beyond U.S. Stocks ↗

May 18, 2026

These three international ETFs offer diversification and surprisingly strong dividends -- with the same low expense ratio of 0.07%.

Via The Motley Fool

Topics Artificial Intelligence ETFs

As U.S. Debt Surpasses GDP, These 2 ETFs Are Emerging Winners in the “Sell America” Trade ↗

May 18, 2026

With U.S. federal debt exceeding 100% of GDP, VXUS and IXUS offer investors international equity exposure as a hedge against rising sovereign risk.

Via MarketBeat

Topics Credit Cards ETFs Economy

BioAge Labs R&D Day: BGE-102 Phase I Shows Big hs-CRP Drops, Sets Up Cardio & DME POC Trials ↗

May 08, 2026

BioAge Labs (NASDAQ:BIOA) used its R&D Day event to provide an update on its lead program, BGE-102, an oral, brain-penetrant inhibitor of the NLRP3 inflammasome that the company is developing across...

Via MarketBeat

Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Case for Dividend Investors ↗

April 08, 2026

Via Chartmill

PTCT Q1 2026 Earnings Transcript ↗

May 08, 2026

PTCT Q1 2026 Earnings Transcript

Via The Motley Fool

This Small Biotech — Taking On AbbVie, Novartis And Sanofi — Just Catapulted Into A Breakout ↗

May 06, 2026

The biotech stock skyrocketed to a two-year high Wednesday on positive results for its skin disease treatment.

Via Investor's Business Daily

Incyte (INCY) Q2 2025 Earnings Transcript ↗

April 28, 2026

Incyte (INCY) Q2 2025 Earnings Transcript

Via The Motley Fool

Novartis Dips As Generics Take A Bite Out Of Its First-Quarter Sales ↗

April 28, 2026

Novartis stock fell early Tuesday on lighter-than-expected first-quarter earnings and sales amid U.S. generic erosion.

Via Investor's Business Daily

Better Pharma Dividend Stock: Novartis vs. Merck ↗

April 17, 2026

Both are great stocks to buy in the current environment, but which one is the better bet?

Via The Motley Fool

Topics Intellectual Property

J&J Shatters Estimates as Oncology and MedTech Power 2026 Outlook Higher

April 15, 2026

Johnson & Johnson (NYSE: JNJ) delivered a robust first-quarter 2026 earnings report on April 14, 2026, handily beating Wall Street expectations and signaling a successful navigation of the long-feared...

Via MarketMinute

Topics Economy Intellectual Property

MedTech Surge and Oncology Resilience Drive Johnson & Johnson to Q1 Earnings Beat

April 14, 2026

In a resounding display of corporate resilience, Johnson & Johnson (NYSE:JNJ) reported first-quarter 2026 financial results that surpassed Wall Street expectations, signaling a successful navigation of...

Via MarketMinute

Topics Bankruptcy Earnings Economy

Big Pharma Deepens AI Ties. What It Means For Novo, Novartis. ↗

April 14, 2026

Novo Nordisk and Novartis deepened their ties to AI companies on Tuesday. And they won't be the last pharma giants to do so.

Via Investor's Business Daily

Topics Artificial Intelligence

The Radiopharmaceutical Renaissance: A Deep Dive into Telix Pharmaceuticals (TLX)

April 13, 2026

As of April 13, 2026, Telix Pharmaceuticals Limited (ASX: TLX; NASDAQ: TLX) stands as a pivotal player in the rapidly evolving field of radiopharmaceuticals—a sector that has transformed from a niche...

Via Finterra

Topics Economy Initial Public Offering

3 Low-Volatility ETFs for Peace of Mind in Turbulent Times ↗

April 13, 2026

Amid confusion about the future trajectory of the war in Iran, the possibility of a continued ceasefire, and the potential implications for the price of oil—and the market in general—it's...

Via MarketBeat

Topics ETFs

The "Liberation Day" Shockwave: US Finalizes 100% Tariffs on Branded Pharmaceutical Imports

April 06, 2026

In a move that has sent shockwaves through the global healthcare industry, the U.S. Administration officially finalized a sweeping new trade policy on April 6, 2026, imposing 100% tariffs on branded...

Via MarketMinute

Topics Economy World Trade

Trump Issues Landmark Executive Order: 100% Tariffs on Imported Patented Drugs to Force Onshoring

April 03, 2026

WASHINGTON, D.C. — In a move that has sent shockwaves through the global healthcare industry, President Trump signed a sweeping executive order yesterday, April 2, 2026, imposing a baseline 100% tariff...

Via MarketMinute

Topics Economy Government Lawsuit

Legend Biotech (LEGN) Q4 2024 Earnings Transcript ↗

April 01, 2026

Legend Biotech (LEGN) Q4 2024 Earnings Transcript

Via The Motley Fool

Topics Earnings Economy World Trade

Legend Biotech (LEGN) Q1 2025 Earnings Transcript ↗

April 01, 2026

Legend Biotech (LEGN) Q1 2025 Earnings Transcript

Via The Motley Fool

Biogen's $5.6 Billion Acquisition of Apellis: A Strategic Pivot into Rare Kidney Diseases

March 31, 2026

In a move that signals a decisive shift away from its traditional focus on neuroscience, Biogen (NASDAQ: BIIB) announced today, March 31, 2026, that it has entered into a definitive agreement to...

Via MarketMinute

Could Investing $10,000 in VYMI Make You a Millionaire? ↗

March 30, 2026

If you want to be a millionaire faster than the S&P 500 index can deliver, this international dividend stock ETF could be the ticket.

Via The Motley Fool

Topics ETFs Stocks

Novartis Bets $2 Billion To Deepen Allergy Drug Pipeline ↗

March 27, 2026

Novartis expands allergy portfolio with $2B acquisition of Excellergy Inc. and their next-gen anti-IgE therapy Exl-111.

Via Benzinga

International ETFs: EEM and IEFA Offer Distinct Global ETF Choices ↗

March 27, 2026

Expense, risk, and sector focus set these two ETFs apart—see which aligns better with your global investing strategy.

Via The Motley Fool

Topics ETFs

Sarepta Therapeutics (SRPT) Stock Surges 34.98% on Breakthrough Clinical Data

March 26, 2026

CAMBRIDGE, MA — March 26, 2026 — Shares of Sarepta Therapeutics (NASDAQ:SRPT) skyrocketed 34.98% in heavy trading today, marking the biotech giant's most explosive single-day gain in over two years....

Via MarketMinute

The Second Act: A Deep-Dive into Corcept Therapeutics and the FDA Approval of Lifyorli

March 26, 2026

March 26, 2026 Introduction Yesterday, March 25, 2026, Corcept Therapeutics (NASDAQ: CORT) reached a defining milestone that has fundamentally altered its investment profile: the early FDA approval of...

Via Finterra

Topics Economy Intellectual Property

The $6.7 Billion Pivot: A Deep Dive into Terns Pharmaceuticals (TERN) and the Merck Acquisition

March 25, 2026

On this Wednesday, March 25, 2026, the biotechnology sector has been electrified by the announcement that Merck & Co. (NYSE: MRK) will acquire Terns Pharmaceuticals, Inc. (NASDAQ: TERN) in an all-cash...

Via Finterra

Topics Initial Public Offering Intellectual Property World Trade

Retirees: Collect a High Dividend While Diversifying Your Portfolio With This ETF ↗

March 24, 2026

The Vanguard International High Dividend Yield ETF holds more than 1,500 stocks and yields 3.3%.

Via The Motley Fool

Topics ETFs Retirement

3 ETFs Built for the Volatile Market We're Seeing in March 2026 ↗

March 22, 2026

These ETFs can handle volatile markets.

Via The Motley Fool

Topics ETFs Economy Stocks

Novartis Strikes $3 Billion Deal For Next-Gen Breast Cancer Drug ↗

March 20, 2026

Novartis to acquire SNV4818 for $3 billion, targeting PIK3CA-mutated breast cancer with a potentially safer, precision-based approach.

Via Benzinga

The High-Stakes Gambit: How Healthcare Giants are 'Front-Loading' Megadeals to Outrun Regulatory Storms

March 18, 2026

In the face of the most aggressive antitrust environment in decades and the sweeping legislative changes of the 2025 "One Big Beautiful Bill Act" (OBBBA), the healthcare sector has not retreated from...

Via MarketMinute

Topics Artificial Intelligence Intellectual Property

Novartis Advances Dermatology Portfolio With Cosentyx FDA Approval For Pediatric Patients ↗

March 16, 2026

FDA approves Novartis' Cosentyx for moderate to severe hidradenitis suppurativa in patients aged 12 and older, expanding treatment options.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

56 57 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Novartis AG Common Stock (NY:NVS)

All News about Novartis AG Common Stock

Starting at $3.75/week.

Subscribe Today